Core Points - The announcement pertains to the listing and circulation of restricted shares for Jiangsu Hanbang Technology Co., Ltd. [1] - The total number of shares to be listed is 1,059,253, which represents 1.20% of the company's total share capital [2][9] - The listing date for these restricted shares is set for November 17, 2025 [4][9] Group 1: Share Issuance Details - The shares being listed are part of the company's initial public offering (IPO) and were allocated through offline placement [5] - The company completed its IPO on May 16, 2025, with a total share capital of 88,000,000 shares, of which 71,459,253 shares are restricted [5] - The lock-up period for these restricted shares was six months from the IPO date [7] Group 2: Compliance and Commitments - All shareholders of the restricted shares have adhered to their commitments regarding the lock-up period [7][8] - The underwriter, CITIC Securities Co., Ltd., confirmed that the company has complied with relevant regulations regarding the listing of these shares [8][9] - There have been no changes in the company's share capital due to profit distribution or other factors since the formation of the restricted shares [6]

证券代码：688755 证券简称：汉邦科技 公告编号：2025-039 江苏汉邦科技股份有限公司 首次公开发行网下配售限售股份上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 1,059,253股。 本次股票上市流通总数为1,059,253股。 本次股票上市流通日期为2025 年 11 月 17 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2025 年 3 月 4 日出具的《关于同意江苏汉邦科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2025〕396 号），江苏汉邦科技股份有限公司（以下简称"公司"） 获准首次公开发行人民币普通股（A 股）2,200.00 万股，并于 2025 年 5 月 16 日 在上海证券交易所科创板上市。公司首次公开发行股票完成后，总股本为 88,000,000 股，其中有限售条件流通股 71,459,253 股，占公司总股本的 81.20%， 无 ...

中信证券股份有限公司 关于江苏汉邦科技股份有限公司 首次公开发行网下配售限售股份上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏汉 邦科技股份有限公司（以下简称"汉邦科技"或"公司"）首次公开发行股票和 持续督导工作的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交 易所科创板股票上市规则》等有关法律法规和规范性文件的要求，就汉邦科技首 次公开发行网下配售限售股份上市流通的事项进行了专项核查： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2025 年 3 月 4日出具的《关于同意江苏汉邦科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2025〕396 号），公司获准首次向社会公开发行人民币普通股（A 股）2,200.00 万股，并于 2025 年 5 月 16 日在上海证券交易所科创板上市。公司 首次公开发行股票完成后，总股本为 88,000,000 股，其中有限售条件流通股 71,459,253 股，占公司总股本的 81.20%，无限售条件流通股 16,540,747 股，占公 司总股本的 18.80%。 本次上 ...

Group 1: Market Overview - The recent volatility in the US stock market has raised concerns about a potential new round of market correction, with the Nasdaq dropping by 2% on November 4 and significant declines in Japanese and Korean markets [2][11] - The tightening of dollar liquidity due to the US government shutdown has been identified as a catalyst for increased market fluctuations, with the Treasury General Account (TGA) rising by $200 billion since October [11] Group 2: North Exchange Market Analysis - The North Exchange's Q3 report shows a revenue growth of 5.3% year-on-year, but net profit decreased by 5.0%, indicating ongoing profitability challenges [10][12] - The return on equity (ROE) improved slightly to 6.1%, with asset turnover at 62.0% and net profit margin at 5.6% [10][12] Group 3: Investment Opportunities in Specific Sectors - The industrial automation sector is highlighted as a growth area, with the company achieving market share increases in low-voltage frequency converters and servo systems from 1.80% and 0.55% in 2019 to 3.02% and 2.30% by 2024 [19] - The human-shaped robot industry is also noted for its potential, with the company leveraging its automation technology to reduce R&D cycles and costs [19][20] Group 4: Pharmaceutical Sector Performance - The pharmaceutical sector reported a total revenue of 18,064 billion yuan in the first three quarters of 2025, with a slight year-on-year decline of 1.9% [21][24] - The innovative drug segment showed a significant revenue increase of 36% in Q3, indicating strong growth potential [21][24]

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly recommending a focus on innovative drugs and sectors with improving performance such as medical devices and CXO [1][10]. Core Insights - The pharmaceutical sector in Q3 2025 showed signs of recovery with a year-on-year revenue growth of 0.6% in Q3, marking the first positive growth in four quarters [1][10]. - Innovative drugs demonstrated a remarkable revenue growth of 36% in Q3 2025, with a turnaround in net profit from a loss of 500 million to a profit of 1.5 billion [10]. - The CXO sector also showed strong performance with a revenue growth of 10.9% and a net profit increase of 47.7% year-on-year, indicating a trend reversal [10]. Summary by Sections Q3 2025 Performance - The A-share pharmaceutical sector, excluding certain companies, achieved total revenue of 1,806.4 billion with a year-on-year decline of 1.9% and a net profit of 139.2 billion, down 5.1% year-on-year [2][11]. - In Q3 2025, total revenue reached 600.4 billion, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][11]. Profitability and Margins - The gross profit for the pharmaceutical sector in Q3 2025 was 189.1 billion, with a gross margin of 31.5%, slightly down from the previous year [5][8]. - The overall net profit margin for Q3 2025 was 6.8%, showing a slight decline compared to the previous year [8]. Cash Flow - The sector reported a net cash inflow from operating activities of 59.1 billion in Q3 2025, representing a year-on-year growth of 17.9% [7][13]. Subsector Performance - The innovative drug sector's revenue growth of 36% and the CXO sector's revenue growth of 10.9% highlight the strong recovery and growth potential within these subsectors [10][11]. - The report emphasizes the importance of focusing on companies such as 恒瑞医药, 长春高新, and 药明康德, which are expected to perform well in the current market environment [1][10].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, indicating a positive outlook for the sector compared to the overall market performance [22]. Core Insights - The pharmaceutical sector has shown signs of recovery, with the first positive year-on-year revenue growth in four quarters, driven by strong performances in the innovative drug and CXO segments [2][11]. - Innovative drugs achieved a remarkable 36% revenue growth in Q3 2025, transitioning from a loss of 500 million to a profit of 1.5 billion, highlighting the sector's high growth potential [11]. - The CXO segment has also shown a significant turnaround, with a year-on-year revenue growth of 10.9% and a net profit increase of 47.7%, expected to maintain mid-to-high growth in the coming year [11]. Summary by Sections Industry Performance - In the first three quarters of 2025, the A-share pharmaceutical and biotechnology sector, excluding certain companies, generated total revenue of 1,806.4 billion yuan, a year-on-year decrease of 1.9%, and a net profit of 139.2 billion yuan, down 5.1% [2][3]. - For Q3 2025, total revenue reached 600.4 billion yuan, reflecting a year-on-year increase of 0.6% but a quarter-on-quarter decrease of 0.4% [2][3]. Profitability Metrics - The gross profit for Q3 2025 was 189.1 billion yuan, with a gross margin of 31.5%, showing a slight decline compared to previous periods [5][8]. - The overall net profit margin for the sector in Q3 2025 was 6.8%, down 0.05 percentage points year-on-year and 1.47 percentage points quarter-on-quarter [8]. Cash Flow Analysis - The sector reported a net cash inflow from operating activities of 59.1 billion yuan in Q3 2025, marking a year-on-year increase of 17.9% and achieving positive growth for two consecutive quarters [7][14]. Subsector Performance - The report highlights the strong performance of the innovative drug and CXO subsectors, with innovative drugs showing a significant recovery and CXO experiencing a positive trend reversal [11][12].

Core Points - In the first ten months of 2025, a total of 87 new companies were listed on the Shanghai Stock Exchange, Shenzhen Stock Exchange, and Beijing Stock Exchange, raising a total of 90.123 billion yuan [1] - Among these, 11 companies were listed on the Sci-Tech Innovation Board, collectively raising 16.952 billion yuan [1] Summary by Category Listing Standards - Seven companies, including Ying Shi Innovation and Hanbang Technology, opted for the first set of listing standards, which requires a market value of no less than 1 billion yuan and positive net profits in the last two years totaling at least 50 million yuan, or a market value of no less than 1 billion yuan with positive net profit in the last year and revenue of at least 100 million yuan [1] - Xi'an Yicai and Yitang Co. chose the fourth listing standard, requiring a market value of no less than 3 billion yuan and revenue of at least 300 million yuan in the last year [1] - He Yuan Bio and Biobetter selected the fifth standard, which requires a market value of no less than 4 billion yuan, with significant market potential and at least one core product approved for phase II clinical trials for pharmaceutical companies [1] Fundraising Details - The actual fundraising amounts for the newly listed companies include: - Xi'an Yicai: 4.63584 billion yuan [2] - He Yuan Bio: 2.59946 billion yuan [2] - Biobetter: 1.60020 billion yuan [2] - Yitang Co.: 2.49748 billion yuan [2] - Ying Shi Innovation: 1.93807 billion yuan [2] - Hanbang Technology: 500.94 million yuan [2] - Shengke Nano: 366.21 million yuan [2] - Haibo Sichuang: 861.10 million yuan [2] - Xingfu Electronics: 1.16800 billion yuan [2] - Sikan Technology: 568.82 million yuan [2] - Saifen Technology: 215.89 million yuan [2]

Core Viewpoint - Hanbang Technology is a leading enterprise in the field of chromatography purification equipment in China, focusing on providing specialized separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] Group 1: Business Performance - In Q3 2025, Hanbang Technology achieved a revenue of 506 million yuan, ranking 23rd out of 42 in the industry, with the industry leader Mindray Medical generating 25.834 billion yuan [2] - The net profit for the same period was 37.017 million yuan, placing the company 25th in the industry, while the top performer, Mindray Medical, reported a net profit of 7.814 billion yuan [2] Group 2: Financial Ratios - As of Q3 2025, Hanbang Technology's debt-to-asset ratio was 34.37%, higher than the industry average of 27.21% [3] - The company's gross profit margin was 38.45%, down from 43.30% year-on-year, and below the industry average of 48.67% [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 7.31% to 8,687, while the average number of circulating A-shares held per shareholder increased by 7.89% to 1,904.08 [5] - The top ten circulating shareholders saw a change, with Dongfanghong Medical Upgrade Stock Initiation A (015052) exiting the list [5] Group 4: Market Outlook - The small molecule liquid chromatography equipment market in China is expected to continue growing, projected to reach 5.2 billion yuan by 2027, with production-level small molecule liquid chromatography systems anticipated to reach 1.87 billion yuan by the same year [5] - Hanbang Technology possesses a differentiated competitive advantage in technology and has established a comprehensive product matrix for chromatography equipment [5] - Earnings per share are projected to be 1.15 yuan and 1.35 yuan for 2025 and 2026, respectively, with corresponding valuations of 41 times and 35 times [5]

Core Viewpoint - Hanbang Technology experienced a slight decline in stock price, with a trading volume of 39.14 million yuan on October 29, 2023, indicating a net outflow in financing activities [1] Financing Summary - On October 29, Hanbang Technology had a financing buy-in amount of 2.85 million yuan and a financing repayment of 5.56 million yuan, resulting in a net financing buy-in of -2.71 million yuan [1] - As of October 29, the total financing and securities lending balance for Hanbang Technology was 77.34 million yuan, which accounts for 10.36% of its circulating market value [1] - There were no shares repaid or sold in the securities lending segment on the same day, with a remaining balance of 0.00 yuan [1] Business Performance Summary - As of September 30, 2023, Hanbang Technology had 8,687 shareholders, a decrease of 7.31% from the previous period, while the average circulating shares per person increased by 7.89% to 1,904 shares [2] - For the period from January to September 2023, Hanbang Technology reported a revenue of 506 million yuan, representing a year-on-year growth of 4.61%, while the net profit attributable to shareholders decreased by 17.27% to 37.02 million yuan [2] - Since its A-share listing, Hanbang Technology has distributed a total of 8.80 million yuan in dividends [2] Company Overview - Hanbang Technology, established on October 28, 1998, is located in Huai'an Economic and Technological Development Zone, Jiangsu Province, and specializes in providing separation and purification equipment, consumables, application technology services, and related technical solutions for the pharmaceutical and life sciences sectors [1] - The revenue composition of Hanbang Technology includes 70.99% from small molecule drug separation and purification equipment, 22.94% from large molecule drug separation and purification equipment, and 6.07% from other sources [1]

Core Viewpoint - Hanbang Technology's stock performance shows a slight increase, with notable financing activities and a mixed financial performance in recent months [1][2]. Group 1: Stock Performance and Financing - On October 28, Hanbang Technology's stock rose by 0.33%, with a trading volume of 27.33 million yuan [1]. - The financing data indicates that on the same day, Hanbang Technology had a financing buy amount of 4.26 million yuan and a net financing buy of 0.48 million yuan, with a total financing balance of 80.05 million yuan, accounting for 10.66% of its market capitalization [1]. - There were no short selling activities reported on October 28, with a short selling balance of 0 yuan [1]. Group 2: Financial Performance - For the period from January to September 2025, Hanbang Technology achieved a revenue of 506 million yuan, representing a year-on-year growth of 4.61% [2]. - The net profit attributable to the parent company for the same period was 37.02 million yuan, showing a year-on-year decrease of 17.27% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for Hanbang Technology was 8,687, a decrease of 7.31% from the previous period [2]. - The average number of circulating shares per shareholder increased by 7.89% to 1,904 shares [2]. - Since its A-share listing, Hanbang Technology has distributed a total of 8.80 million yuan in dividends [3].